When untreated, sleep apnea is linked to serious and costly conditions, including drug-resistant hypertension, obesity, congestive heart failure, type-2 diabetes, atrial fibrillation and more.
Untreated sleep apnea costs the U.S. approximately $150 billion annually, due to the healthcare costs associated with these untreated conditions, as well as loss of productivity, workplace accidents and motor vehicle accidents.
Current solutions are not working. Continuous positive airway pressure (CPAP) therapy accounts for 85% of diagnosed sleep apnea patients, yet nearly half don’t comply with the therapy. The devices are cumbersome, loud, uncomfortable and overall intrusive.
Patients need a better option.
Invicta Medical is changing the sleep apnea treatment paradigm from high-cost, complex machines, to smart, comfortable and cost-effective solutions.
Invicta’s intelligent neurostimulation wearable is designed to address the shortcomings of existing therapies, which are expensive, intrusive and yield low patient compliance rates.
Invicta has raised $28.6 million in funding since 2013 and is backed by international investors and Tier 1 investment firms.
Invicta’s Board of Directors have extensive operational and financial experience in industries ranging from medical technologies and life sciences to semiconductors to robotics, while its Scientific Advisors hail from top universities and medical institutions, including Stanford University, John Hopkins University, Karolinska Institute and the University of Pittsburgh Medical Center.